Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174452 | 0.92 | CTSS (0.37) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL3166486 | 0.91 | CTSS (0.36) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL3174441 | 0.89 | JAK3 (0.36) | CTSLCTSSCTSBCTSDCTSK | |
| SCHEMBL3166667 | 0.86 | GPR119 (0.40) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL3168776 | 0.86 | CTSL (0.34) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL3169120 | 0.85 | STK17B (0.36) | CTSLCTSSCTSBCTSDJAK3 | |
| SCHEMBL3173726 | 0.83 | CTSL (0.35) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL3166419 | 0.83 | CTSL (0.35) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL8205623 | 0.83 | CTSL (0.35) | CTSLCTSSCTSBCTSKGPR119 | |
| SCHEMBL8193158 | 0.83 | CTSL (0.35) | CTSLCTSSCTSBCTSKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008052934-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | CTSL 9/4885CTSS 15/4885CTSB 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.